CISLD-8
Phase 1 Completed
30 enrolled
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
Phase 1 Completed
23 enrolled
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Phase 1 Completed
145 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors
Phase 1 Completed
17 enrolled
Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads
Phase 1 Completed
15 enrolled
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Phase 1 Completed
14 enrolled
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Phase 1 Completed
67 enrolled
GLYCAR
Phase 1 Completed
9 enrolled
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
Phase 1 Completed
55 enrolled 30 charts
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 1 Completed
29 enrolled
Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
Phase 1 Completed
184 enrolled 20 charts
GEN2
Phase 1 Completed
61 enrolled
OPTIM
Phase 1 Completed
13 enrolled
Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC
Phase 1 Completed
10 enrolled 14 charts
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Phase 1 Completed
15 enrolled
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
Phase 1 Completed
58 enrolled 17 charts
DUET-3
Phase 1 Completed
198 enrolled
A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma
Phase 1 Completed
146 enrolled
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
Phase 1 Completed
5 enrolled
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
Phase 1 Completed
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
Phase 1 Completed
46 enrolled
A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma
Phase 1 Completed
104 enrolled 41 charts
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Phase 1 Completed
271 enrolled
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
Phase 1 Completed
128 enrolled 27 charts
An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors
Phase 1 Completed
16 enrolled
TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers
Phase 1 Completed
38 enrolled
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Phase 1 Completed
37 enrolled
DUET-4
Phase 1 Completed
78 enrolled
Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)
Phase 1 Completed
36 enrolled
DUET-2
Phase 1 Completed
150 enrolled
A Study of TCR-Redirected T Cell Infusion to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation
Phase 1 Completed
13 enrolled
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 1 Completed
139 enrolled
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Phase 1 Completed
174 enrolled 68 charts
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
Phase 1 Completed
57 enrolled
A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors
Phase 1 Completed
182 enrolled
A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
Phase 1 Completed
12 enrolled
Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
Phase 1 Completed
5 enrolled
Chimeric Antigen Receptor T Cells Targeting Glypican-3
Phase 1 Completed
9 enrolled
LNA-i-miR221
Phase 1 Completed
17 enrolled
Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
Phase 1 Completed
27 enrolled 13 charts
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Phase 1 Completed
40 enrolled
Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Phase 1 Completed
16 enrolled
Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)
Phase 1 Completed
24 enrolled
LIP-RE-I
Phase 1 Completed
16 enrolled
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
Phase 1 Completed
28 enrolled
A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies
Phase 1 Completed
85 enrolled
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
Phase 1 Completed
20 enrolled
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Phase 1 Completed
22 enrolled